Informationen:
Fehler:
ID
14654
Beschreibung
Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?; ODM derived from: https://clinicaltrials.gov/show/NCT00534261
Link
https://clinicaltrials.gov/show/NCT00534261
Stichworte
Versionen (1)
- 25.04.16 25.04.16 -
Hochgeladen am
25. April 2016
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Relapsing Remitting Multiple Sclerosis NCT00534261
Eligibility Relapsing Remitting Multiple Sclerosis NCT00534261
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Relapsing Remitting Multiple Sclerosis NCT00534261
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Relapsing remitting multiple sclerosis
Item
relapsing remitting multiple sclerosis
boolean
C0751967 (UMLS CUI [1])
Interferon naïve
Item
interferon naïve
boolean
C0332155 (UMLS CUI [1,1])
C0751599 (UMLS CUI [1,2])
C0751599 (UMLS CUI [1,2])
Eligble for interferon beta
Item
eligible for interferon beta-1a (avonex®) therapy as per summary of product characteristics:
boolean
C0751599 (UMLS CUI [1,1])
C0013893 (UMLS CUI [1,2])
C0013893 (UMLS CUI [1,2])
Date of relapse
Item
subject has had relapsing ms for > 1 year
boolean
C0807712 (UMLS CUI [1])
MS exacerbation
Item
subject has had experienced 2 exacerbations in the last 2 years
boolean
C0581392 (UMLS CUI [1])
EDSS score
Item
subject had an edss [5] score of < 5.5
boolean
C0451246 (UMLS CUI [1])
Ambulant patient
Item
subject was ambulant
boolean
C0029921 (UMLS CUI [1])
Progressive MS
Item
diagnosis of ms defined as progressive
boolean
C0751964 (UMLS CUI [1])
Comorbidity affecting Interferon beta therapy
Item
history of any significant cardiac, hepatic, pulmonary, or renal disease; immune deficiency; or other medical conditions that would preclude therapy with interferon beta
boolean
C0009488 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0751599 (UMLS CUI [1,3])
C0392760 (UMLS CUI [1,2])
C0751599 (UMLS CUI [1,3])
Allergy to human albumin
Item
history of severe allergic or anaphylactic reactions or history of hypersensitivity to human albumin
boolean
C0020517 (UMLS CUI [1,1])
C0304925 (UMLS CUI [1,2])
C0304925 (UMLS CUI [1,2])
Seizure
Item
history of seizures within the 3 months prior to starting this study
boolean
C0036572 (UMLS CUI [1])
Drug intolerance
Item
history of intolerance to acetaminophen (paracetamol), ibuprofen, naproxen or other nsaids, that would preclude use of at least one of these during the study
boolean
C0277585 (UMLS CUI [1])
Intolerance to interferons
Item
history of intolerance to interferons
boolean
C0277585 (UMLS CUI [1,1])
C0751599 (UMLS CUI [1,2])
C0751599 (UMLS CUI [1,2])
Previous therapy with interferon beta
Item
previous use of interferon beta
boolean
C0751599 (UMLS CUI [1,1])
C2114510 (UMLS CUI [1,2])
C2114510 (UMLS CUI [1,2])
Gynaecological status
Item
female subjects who were pregnant or breast-feeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
Contraception
Item
for female subjects, unless postmenopausal or surgically sterile, unwillingness to practice effective contraception
boolean
C0700589 (UMLS CUI [1])